Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 8314 results

  1. Digital self-help for eating disorders: early value assessment

    In development Reference number: GID-HTE10058 Expected publication date: TBC

    Health technology evaluations
    In development

  2. Algorithms applied to spirometry to support the diagnosis of lung conditions in primary care and community diagnostic centres

    In development Reference number: GID-HTE10065 Expected publication date:  02 April 2026

    Health technology evaluations
    In development

  3. Pulmonary artery pressure technologies for remote monitoring of chronic heart failure

    In development Reference number: GID-DG10087 Expected publication date:  05 February 2026

    Diagnostics guidance
    In development

  4. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  5. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG ID6454

    In development Reference number: GID-TA11592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over ID6579

    In development Reference number: GID-TA11780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development

  8. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    In development Reference number: GID-TA11468 Expected publication date:  14 May 2026

    Technology appraisal guidance
    In development

  9. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    Awaiting development Reference number: GID-TA11565 Expected publication date:  21 May 2026

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]

    In development Reference number: GID-TA11115 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  12. Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

    In development Reference number: GID-TA11669 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  13. Seladelpar for previously treated primary biliary cholangitis [ID6429]

    In development Reference number: GID-TA11540 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]

    In development Reference number: GID-TA11767 Expected publication date:  04 November 2026

    Technology appraisal guidance
    In development

  15. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date:  22 April 2026

    Technology appraisal guidance
    In development